Personalized Binuclear Enzyme Inhibition Platform

A next-generation platform for treating diseases and conditions mediated by binuclear enzymes, leveraging AI-driven molecular design, personalized skin analysis, and transdermal delivery to provide customized and effective treatments.

The original patent disclosed diarylalkane compounds as potent inhibitors of binuclear enzymes, but it had limitations in terms of compound synthesis, skin penetration, and personalized treatment. The new inventive concept addresses these limitations by introducing AI-driven molecular design, personalized skin analysis, and transdermal delivery, enabling more effective and targeted treatments.

The platform comprises a database of diarylalkane compounds, a skin analysis module, and a recommendation engine that selects a customized diarylalkane composition based on an individual's skin type, condition, and desired outcome. The AI-driven molecular design system predicts optimal molecular structures for inhibiting binuclear enzymes and generates novel compounds for further testing and development. The transdermal delivery system ensures sustained and targeted delivery of the active ingredient. The novel class of diarylalkane compounds having modified general structures enhances bioavailability, stability, or skin penetration.

The new claims introduce AI-driven molecular design, personalized skin analysis, and transdermal delivery, which are not present in the original patent. The combination of these elements provides a novel and non-obvious solution for treating diseases and conditions mediated by binuclear enzymes.

Alternative embodiments may include the use of other AI algorithms, different transdermal delivery systems, or additional skin analysis parameters. Variations may include the application of this platform to other diseases and conditions beyond skin pigmentation, such as cancer or neurodegenerative diseases.

The personalized binuclear enzyme inhibition platform has significant commercial potential in the cosmetics and pharmaceutical industries, particularly in the areas of skin care and dermatology. The platform's ability to provide customized and effective treatments could disrupt the existing market and create new opportunities for companies and researchers.